Functional status and quality of life in patients surviving 10 years after lung transplantation.
Although many lung allograft recipients achieve long-term survival, there is a lack of published data regarding these patients' functional status and quality of life (QoL). We evaluated all 10-year survivors at our institution and, utilizing the SF-36 questionnaire, compared their QoL to population normative and chronic illness data. Twenty-eight (29%) of 96 patients survived > or =10 years following 11 single, 6 bilateral and 11 heart-lung procedures. At the most recent evaluation, median FEV(1) in single and double lung recipients was predicted to be 54% and 74%, respectively. Five (18%) patients had BOS score 0, 13 (46%) BOS 1, 5 (18%) BOS 2 and 5 (18%) BOS 3 and median time to BOS was 7 years. Four (14%) patients required renal replacement therapy. Three patients (11%) developed symptomatic osteoporosis, 2 (7%) post-transplant lymphoma and 1 (4%) an ischaemic stroke. Scores for physical function, role-physical/emotional and general health, but not mental health and bodily pain, were significantly lower compared to normative and chronic illness data. Energy and social-function scores were significantly lower than normative data alone. Long-term survival after lung transplantation is characterized by an absence or delayed development of BOS, low iatrogenic morbidity and preserved mental, but reduced physical health status.
Rutherford
Robert M
RM
Department of Respiratory Medicine, Freeman Hospital, University of Newcastle upon Tyne, Newcastle upon Tyne, UK. robert.rutherford@northumbria-healthcare.nhs.uk
Fisher
Andrew J
AJ
Hilton
Colin
C
Forty
Jonathan
J
Hasan
Asif
A
Gould
Francis K
FK
Dark
John H
JH
Corris
Paul A
PA
D000293:Adolescent; D000328:Adult; D001989:Bronchiolitis Obliterans / Q000175:diagnosis* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006304:Health Status; D006305:Health Status Indicators; D016041:Heart-Lung Transplantation / Q000379:methods* / Q000523:psychology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007668:Kidney / Q000473:pathology; D016040:Lung Transplantation / Q000379:methods* / Q000523:psychology*; D008297:Male; D009369:Neoplasms / Q000209:etiology; D011788:Quality of Life; D017582:Renal Replacement Therapy; D011795:Surveys and Questionnaires; D013997:Time Factors; D014652:Vascular Diseases / Q000209:etiology
D007166:Immunosuppressive Agents